Loading...

EOLS - Evolus, Inc.

Analyst Coverage Initiated Signal for 06-23-2022
Analyst Coverage Initiated: EOLS rating Buy by Needham
Price Target: $18



Stock Signal Information


Signal

Analyst Coverage Initiated Stock
Report Date: 06-23-2022
Symbol: EOLS - Evolus, Inc.
Sector: Healthcare
Industry: Drug Manufacturers—Specialty & Generic
Analyst Coverage Initiated: EOLS rating Buy by Needham
Price Target: $18

  EOLS Technical Chart

Company Contact

Evolus, Inc. (EOLS)
520 Newport Center Dr Ste 1200
Newport Beach, CALIFORNIA 92660
Phone: 19492844555
Website: https://www.evolus.com
CEO: Mr. David Moatazedi


Company Profile

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was founded in 2012 and is headquartered in Newport Beach, California.